Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

Wegener's Granulomatosis Clinical Trial

Official title:

A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener's Granulomatosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00468208
• Other study ID #: RDCRN 5522
• Secondary ID: U54AR057319
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: April 30, 2007
• Last updated: December 15, 2015
• Start date: February 2008
• Est. completion date: August 2011

Study information

• Verified date: December 2015
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys. The purpose of this study is to determine the safety and effectiveness of the medication abatacept in treating adults with mild relapsing WG.

Description:

Current standard treatment for WG involves various medications and is based on disease severity. Unfortunately, more than 50% of people experience a relapse after remission, placing them at risk for additional organ damage and medication toxicity. To prevent this, safer and more effective treatments for mild relapses are needed. Several studies have shown that activated T cells, a type of white blood cell important in regulating immune responses, play a role in WG. Abatacept, an immunoglobulin-based medication approved by the FDA to treat rheumatoid arthritis, acts by preventing T-cell activation and may be useful in treating mild relapses of WG. The purpose of this study is to determine the safety and effectiveness of abatacept in treating adults with mild relapsing WG.

Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter. A participant's abatacept dose is based on body weight and will remain the same throughout the study. Participants who are receiving maintenance immunosuppressive medications consisting of methotrexate, azathioprine, or mycophenolate mofetil at the time of enrollment will remain on these medications without dosage increase or reduction. Eligible participants may be on up to prednisone 15mg daily at the time of relapse. Following the development of relapse, participants may be treated with up to prednisone 30mg daily if necessary, but must to be back to the same dose that they had been on prior to relapse by Month 2. All study visits include medication review, physical exam, blood and urine collection, and questionnaires. A chest x-ray, computed tomography (CT) scan of the chest and sinuses, and lung function testing will occur at some study visits. Participants whose symptoms did not improved by Month 2 will be taken off abatacept. Any participants undergoing early termination or, after common closing, will undergo three follow-up study visits at 1, 3, and 6 months after the end of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of WG, meeting at least 2 of the 5 modified American College of Rheumatology (ACR) criteria. More information about this criterion can be found in the protocol.

• Relapse of WG within the past 28 days where disease activity is confined to one or more of the following sites and where the symptoms/signs are of such a nature that the usual treatment would consist of the reinstitution or increase in GC to no more than prednisone 30mg daily and/or an increase or addition of a second immunosuppressive agent other than CYC (more specific information about this criterion can be found in the protocol):

1. Sinonasal disease

2. Oral mucosa ulceration

3. Skin disease

4. Musculoskeletal disease

5. Pulmonary parenchymal disease

6. Mild ocular disease

7. Subglottic inflammation without significant stenosis

8. Otic disease

9. Breast involvement

10. Urogenital involvement

11. Other mild disease

• Age of 15 years or older

• Willing and able to undergo treatment and attend follow-up visits

• Willing to use effective forms of contraception throughout the study

Exclusion Criteria:

• Disease involvement that does not meet the criteria for mild disease. More information about this criterion can be found in the protocol.

• Disease activity that would usually be treated first with cyclophosphamide

• Presence of disease activity for which the investigator would normally treat the participant with more than prednisone 30 mg daily.

• Receiving cyclophosphamide at study entry

• Treatment with prednisone at a dose of more than 15 mg daily at the time of relapse. Subjects will be eligible if prednisone was initiated or dose increased in the period between relapse and study enrollment provided that the prednisone dose was 15 mg daily or less at the time when the relapse occurred, the prednisone dosage was increased no higher than 30 mg daily following the recognition of relapse, and that the dosage increase was made no more than 28 days prior to enrollment.

• Active infection

• HIV infected, hepatitis C virus infected, or positive for hepatitis B

• Unable to follow through with study participation

• Cytopenia, defined as platelet count less than 80,000/mm3, absolute neutrophil count less than 1500/mm3, OR hematocrit less than 20%

• Kidney insufficiency

• Use of illegal drugs

• Any other uncontrolled disease that would prevent participation

• History of cancer. More information about this criterion can be found in the protocol.

• Received an investigational medication or procedure within 30 days of study entry

• Received a live vaccine within 4 weeks of study entry

• Positive tuberculin skin test. More information about this criterion can be found in the protocol.

• Tuberculosis as indicated by radiographic evidence

• Past treatment with rituximab within the past 12 months, or past treatment with rituximab more than 12 months ago where the B lymphocyte count has not returned to normal

• Certain other diseases. More information about this criterion can be found in the protocol.

• Pregnant or breastfeeding

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Wegener Granulomatosis
• Wegener's Granulomatosis

Intervention

Drug:
• Abatacept
A participant's abatacept dose depended on body weight and will remain the same throughout the study: 500 mg of abatacept for body weight less than 60 kg 750 mg of abatacept for body weight between 60 and 100 kg 1000 mg of abatacept for body weight greater than 100 kg Abatacept is administered in a 30-minute intravenous infusion.

Locations

Country	Name	City	State
United States	The Johns Hopkins Vasculitis Center	Baltimore	Maryland
United States	Boston University School of Medicine	Boston	Massachusetts
United States	Cleveland Clinic	Cleveland	Ohio
United States	Mayo Clinic College of Medicine	Rochester	Minnesota

Sponsors (4)

Lead Sponsor	Collaborator
University of Pennsylvania	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Rare Diseases (ORD), Rare Diseases Clinical Research Network

Country where clinical trial is conducted

United States, 

References & Publications (4)

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 Sep 15;353(11):1114-23. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311. — View Citation

Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, Ytterberg SR, Hoffman GS, Krischer JP, Merkel PA; Vasculitis Clinical Research Consortium. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangi — View Citation

Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003 Apr 15;114(6):463-9. — View Citation

Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005 Jan 27;352(4):351-61. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of Abatacept - Number of Participants With Adverse Events	This study examined the safety profile of this agent when used in Wegener's granulomatosis. Information was gathered on all adverse events with specific events being identified in the protocol for analysis that included the following: Infection; Infusion reactions; Cytopenias; Transaminase elevation; Skin reactions; GI side effects; Malignancy; All adverse events were reportable for this study.	Measured continuously from the screening visit through to the 6 month post-treatment study visit, up to 3 years and 4 months.	Yes
Secondary	Disease Remission	Disease remission was measured by a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0.; The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63.	Measured monthly until common closing or early termination,up to 3 years and 4 months.	No
Secondary	Disease Improvement	Disease improvement was measured by a reduction in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG).; The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63.	Measured monthly until common closing or early termination, up to 3 years and 4 months.	No
Secondary	Meeting Common Closing	The number of subjects that reached the common closing date.	Number assessed at the time of common closing, up to 3 years and 4 months.	No
Secondary	Disease Relapse	Disease relapse was measured by a rise in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of greater than or equal to 1 after achieving remission.; The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63.	Measured monthly until common closing or early termination, up to 3 years and 4 months.	No

External Links

•   Cleveland Clinic Center for Vasculitis Care and Research website
•   Vasculitis Clinical Research Consortium website